EyePoint Pharmaceuticals' Duravyu shows promising Phase 2 results in DME, with potential for less frequent dosing. Check out ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period - halving the number of injections that are ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...

Additionally, patients who switched from EYLEA ® (aflibercept) Injection 2 mg to EYLEA HD at the beginning ... randomized at baseline to either 3- or 4-month dosing intervals (after three initial ...

However, the current treatment paradigm of monthly eye injections can make it challenging for patients ... defined criteria starting at week 32 for patients who receive EYLEA or EYLEA HD after 3 ...

However, the current treatment paradigm of monthly eye ... EYLEA HD patients dosed every 8 weeks achieving non-inferior visual acuity gains compared to those receiving EYLEA ® (aflibercept ...

You may experience temporary visual changes after an EYLEA HD or EYLEA injection and associated eye exams; do not drive or use machinery until your vision recovers sufficiently. For additional ...

Injection 8 mg to treat patients with macular edema following retinal vein occlusion (RVO). The intended patient population includes those with central, branch and hemiretinal vein occlusions. Eylea ...

In the trial, patients treated with EYLEA HD every 8 weeks (after initial ... broad group of patients and eye care professionals. This includes EYLEA HD, which has been developed with the aim of ...

These impressive data from QUASAR demonstrated that EYLEA ... and eye care professionals. This includes EYLEA HD, which has been developed with the aim of extending the time between injections ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.